Curia Missouri
United States Updated 9 July 2026
Curia Missouri is an API manufacturer based in United States. It holds 7 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 2 December 2025 as NAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 2 December 2025 NAI US FDA
- 2 August 2019 NAI US FDA
- 9 February 2017 NAI US FDA
- 8 August 2014 NAI US FDA
- 6 January 2012 NAI US FDA
- 22 April 2010 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Springfield, United States | 1941037 |
What they file, and where
| Molecule | Regulators | Docs |
| Choline Fenofibrate | US FDA | 1 |
| Dexmethylphenidate | US FDA | 1 |
| Lacosamide | US FDA | 1 |
| Methylphenidate | US FDA | 1 |
| Regadenoson | US FDA | 1 |
| Sodium Oxybate | US FDA | 1 |
| Tapentadol | US FDA | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Curia Missouri comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 2 December 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates